A glass material that includes: from about 0.55 to about 0.85 mole fraction of SiO.sub.2; from about 0.01 to about 0.23 mole fraction of Na.sub.2O, K.sub.2O, or a combination of Na.sub.2O and K.sub.2O; from about 0.05 to about 0.28 mole fraction of: Y.sub.2O.sub.3, BaO, or a combination of Y.sub.2O.sub.3 and BaO; and optionally Ta.sub.2O.sub.5. In the glass material, the sum of the Y.sub.2O.sub.3, the BaO and the optional Ta.sub.2O.sub.5 is from about 0.10 to about 0.31 mole fraction. The glass material may be in the form of microspheres. The microspheres may be used for vascular embolization and/or radiologic imaging.

The present invention relates to electrochemically initiated bioadhesive compositions comprising biocompatible polymers containing derivatives of diazonium, arylsulfonium, or diaryliodonium in general, and to their use in tissue fixation, in particular.

Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.

The invention relates to non-biodegradable embolisation microspheres comprising a cross-linked matrix, the matrix being based on at least: a) from 20% to 95% of hydrophilic monomer; b) from 1% to 15% of a non-biodegradable hydrophilic cross-linking monomer; and c) from 1.5% to less than 6% of transfer agent selected from alkyl halides and cycloaliphatic or aliphatic thiols having in particular from 2 to 24 carbon atoms, and optionally having another functional group selected from amino, hydroxy and carboxy groups. The invention further relates to a pharmaceutical composition comprising non-biodegradable embolisation microspheres according to the invention in conjunction with a pharmaceutically acceptable vehicle, advantageously for parenteral administration. The invention further relates to a kit comprising a pharmaceutical composition comprising non-biodegradable embolisation microspheres according to the invention in conjunction with a pharmaceutically acceptable vehicle for parenteral administration, and at least one injection means.

A method for promoting spine fusion inside intersomatic cages, comprising placing a fusion cage between two vertebral bodies, and injecting a bone cement paste inside said fusion cage, said bone cement paste containing a powder component comprising α-tricalcium phosphate (α-TCP) particles having an average size greater than or equal to 9 μm, and a liquid component comprising blood.

A kit of parts suitable for preparing a cured biocompatible polymer material, the kit including at least 2 containers each containing a fluid component, which components—when mixed—form a fluid curable biocompatible polymer composition, which upon curing forms the cured biocompatible silicone polymer material.

Blockchain environments may mix-and-match different encryption, difficulty, and/or proof-of-work schemes when mining blockchain transactions. Each encryption, difficulty, and/or proof-of-work scheme may be separate, stand-alone programs, files, or third-party services. Blockchain miners may be agnostic to a particular coin's or network's encryption, difficulty, and/or proof-of-work schemes, thus allowing any blockchain miner to process or mine data in multiple blockchains. GPUs, ASICs, and other specialized processing hardware components may be deterred by forcing cache misses, cache latencies, and processor stalls. Hashing, difficulty, and/or proof-of-work schemes require less programming code, consume less storage space/usage in bytes, and execute faster. Blockchain mining schemes may further randomize byte or memory block access, further improve cryptographic security.

An embolization system and methods for controlling solidification of embolic compositions comprising a first and a second embolic component that react with each other in vivo at a target site to form an embolic material, with the embolic components being dilutable in physiological fluids so that they do not form an embolic composition at a site that is not desired.

A composition for the adhesion of biological tissues to one another, for the adhesion of a material to a biological tissue, for the adhesion of an adhesive or of a substance to the surface of a biological tissue, for blocking an orifice in a biological tissue, for reinforcing a biological tissue and/or for fixing and stabilising a biological tissue. A monomer that is polymerisable under the effect of ultraviolet (UV) radiation and in that the viscosity of said composition is less than 10 mPa.Math.s at 20° C.

The invention primarily relates to fastening and stabilizing tissues, implants, and/or bondable materials, such as the fastening of a tissue and/or implant to a bondable material, the fastening of an implant to tissue, and/or the fastening of an implant to another implant. This may involve using an energy source to bond and/or mechanically to stabilize a tissue, an implant, a bondable material, and/or other biocompatible material. The invention may also relate to the use of an energy source to remove and/or install an implant and/or bondable material or to facilitate solidification and/or polymerization of bondable material.